The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains
Read More
post
Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group
Read More
post
Navigating Analytical Method Comparability and Equivalency Under ICH Q14: A New Era for Analytical Procedure Lifecycle Management
Read More
case-study
From CDMO to In-House cGMP Manufacturing: Scaling Success in Cell Therapy Technology Transfer
Read More
Let's move from science to success.
Let’s Talk